Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sarah Cannon Research Institute | Researchclopedia

Back to institutions

Sarah Cannon Research Institute

Londoneducation

1,388

Works

92,237

Citations

119

h-index

Top Research Topics

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations

Top Researchers

Mark A. Rubin University of Bern

1,524 works165,725 citationsh-index: 186

Recent Research

Base Editing of <i>HBG1</i> and <i>HBG2</i> Promoters for Sickle Cell Disease

Ashish O. Gupta,Akshay Sharma,et al.

20263 citations

HER2/EGFR in Cancer Research

Cancer Treatment and Pharmacology

Advanced Breast Cancer Therapies

Prostate Cancer Treatment and Research

Cancer Genomics and Diagnostics

Gastric Cancer Management and Outcomes

Chronic Lymphocytic Leukemia Research

Radiopharmaceutical Chemistry and Applications

Lymphoma Diagnosis and Treatment

Eric P. Winer Harvard University

1,618 works128,848 citationsh-index: 170

Josep Tabernero Hebron University

2,703 works126,607 citationsh-index: 146

José Baselga Hebron University

1,379 works117,682 citationsh-index: 143

Charles S. Fuchs Yale Cancer Center

1,715 works113,226 citationsh-index: 171

Mitch Dowsett Royal Marsden NHS Foundation Trust

1,593 works110,897 citationsh-index: 147

64P Molecularly unselected immune-based versus non-immune-based trials: Outcomes in refractory metastatic castrate resistant prostate cancer (mCPRC) at Sarah Cannon Research Institute (SCRI) UK

Khobe Chandran,Hamad Almarzouq,et al.

20260 citations

CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat β-Thalassemia

Haydar Frangoul,Rabi Hanna,et al.

20263 citations

CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell Disease

Rabi Hanna,Haydar Frangoul,et al.

20263 citations

89O BMS-986504 with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007

B. George,Konstantinos Leventakos,et al.

20260 citations

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid Tumors

María Vieito,E. Fontana,et al.

20260 citations